-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Nautilus Biotechnology, Raises Price Target to $4

Benzinga·02/27/2026 15:41:33
Listen to the news
Guggenheim analyst Subbu Nambi maintains Nautilus Biotechnology (NASDAQ:NAUT) with a Buy and raises the price target from $2.5 to $4.